Cover Image
Market Research Report

Global Allergic Rhinitis Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 759917
Published Content info 113 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Allergic Rhinitis Drugs Market 2019-2023
Published: December 7, 2018 Content info: 113 Pages
Description

About this market:

The rise in R&D of new therapies is expected to drive growth in the market. There has been an increase in the prevalence of allergic diseases globally. If these diseases are not managed at an early stage, allergic diseases such as rhinitis can increase the risk of asthma in patients. Several organizations are trying to understand the pathogenesis of these diseases. Technavio's analysts have predicted that the allergic rhinitis drugs market will register a CAGR of close to 4% by 2023.

Market Overview:

Increasing prevalence of allergic rhinitis

The increase in the prevalence of allergic rhinitis is expected to increase the pool of patients as well as the consumption of medicine. This worldwide increase in the incidence of allergic rhinitis is likely to drive growth of the allergic rhinitis drugs market.

Competition from generics

The increase in competition from generics is expected to adversely affect the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the allergic rhinitis drugs market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Sanofi and Stallergenes Greer the competitive environment is quite intense. Factors such as the increase in the prevalence of allergic rhinitis and the rise in R&D of new therapies, will provide considerable growth opportunities to allergic rhinitis drugs manufactures. ALK-Abello, GlaxoSmithKline, Merck, Sanofi, and Stallergenes Greer are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30440

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis
  • PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Antihistamines - Market size and forecast 2018-2023
  • Intranasal corticosteroids - Market size and forecast 2018-2023
  • Immunotherapies - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
  • PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Market trends

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALK-Abello
  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Stallergenes Greer

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 02: Global respiratory drugs market
  • Exhibit 03: Segments of global respiratory drugs market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Pipeline drugs in clinical trials
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Antihistamines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Antihistamines - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Intranasal corticosteroids - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Intranasal corticosteroids - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Immunotherapies - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Immunotherapies - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by product
  • Exhibit 30: Customer landscape
  • Exhibit 31: Market share by geography 2018-2023 (%)
  • Exhibit 32: Geographic comparison
  • Exhibit 33: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Key Leading Countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: ALK-Abello - Vendor overview
  • Exhibit 49: ALK-Abello - Business segments
  • Exhibit 50: ALK-Abello - Organizational developments
  • Exhibit 51: ALK-Abello - Geographic focus
  • Exhibit 52: ALK-Abello - Key offerings
  • Exhibit 53: GlaxoSmithKline - Vendor overview
  • Exhibit 54: GlaxoSmithKline - Business segments
  • Exhibit 55: GlaxoSmithKline - Organizational developments
  • Exhibit 56: GlaxoSmithKline - Geographic focus
  • Exhibit 57: GlaxoSmithKline - Segment focus
  • Exhibit 58: GlaxoSmithKline - Key offerings
  • Exhibit 59: Merck - Vendor overview
  • Exhibit 60: Merck - Business segments
  • Exhibit 61: Merck - Organizational developments
  • Exhibit 62: Merck - Geographic focus
  • Exhibit 63: Merck - Segment focus
  • Exhibit 64: Merck - Key offerings
  • Exhibit 65: Sanofi - Vendor overview
  • Exhibit 66: Sanofi - Business segments
  • Exhibit 67: Sanofi - Organizational developments
  • Exhibit 68: Sanofi - Geographic focus
  • Exhibit 69: Sanofi - Segment focus
  • Exhibit 70: Sanofi - Key offerings
  • Exhibit 71: Stallergenes Greer - Vendor overview
  • Exhibit 72: Stallergenes Greer - Business segments
  • Exhibit 73: Stallergenes Greer - Organizational developments
  • Exhibit 74: Stallergenes Greer - Geographic focus
  • Exhibit 75: Stallergenes Greer - Key offerings
Back to Top